The detection of designer opioids is complicated by their structural diversity and the constant emergence of new variants. Standard drug tests may not identify these substances, necessitating advanced analytical techniques like mass spectrometry and liquid chromatography. Moreover, the rapid pace at which new compounds are developed often outstrips the ability of laboratories to update their testing protocols.
